Biomarkers · Cardiac & Hemodynamics

Left Ventricular Ejection Fraction (LVEF)

Higher values go with lower risk of death. Not measured in our NHANES panel. The curve is drawn from the published study (source below).

LVEF and risk of death

Published curve higher than the NHANES fitNHANES fit higher

Risk of death relative to the curve's reference value, drawn from the published study (source below).

Published risk of death1.60×asymptomatic LV systolic dysfunction (visually estimated EF <=50%, no CHF) vs normal… (95% CI 1.10–2.40) · Framingham Study participants (n=4257, 1860 men) with routine echocardiography, community-based, USA; up to 12 years follow-up

What studies found when this marker was changed

They describe what happened in those study groups, not a recommendation. See all catalogued interventions.

Measured changes in LVEF, study by study

4 effects with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Green points move the marker the way lower risk of death lies; amber the other way. Study results in the groups studied, not predictions for a person.

Each row is one study: what was changed, the effect it reported on this marker, and the source.
Type	Intervention	Reported effect	Evidence	Source
pharmacologic	Sacubitril/valsartan in patients with heart failure receiving dialysis	LVEF +4.03 percentage points (95% CI 2.90 to 5.16) vs conventional therapy	meta-analysis	Nguyen DV, Le TN, Truong BQ, et al. Eur J Heart Fail. 2025.
pharmacologic	Corticosteroid therapy (e.g. prednisone) in viral myocarditis	LVEF +7.36 percentage points (95% CI 4.94 to 9.79) at 1-3 months	meta-analysis	Chen HS, Wang W, Wu SN, Liu JP. Cochrane Database Syst Rev. 2013.

Things that worsen it

Each row is one study: what was changed, the effect it reported on this marker, and the source.
Type	Condition or exposure	Reported effect	Evidence	Source
pharmacologic	Aficamten 5-20 mg daily for 24 weeks in symptomatic obstructive hypertrophic cardiomyopathy	LVEF -4.8 percentage points (95% CI -6.4 to -3.3) vs placebo at 24 weeks	RCT	Hegde SM, Claggett BL, Wang X, et al. J Am Coll Cardiol. 2024.
pharmacologic	Mavacamten 5 mg/day (titrated 1-15 mg) for 48 weeks in nonobstructive hypertrophic cardiomyopathy	LVEF -5.3 percentage points (95% CI -5.9 to -4.1) vs placebo at 48 weeks	RCT	Desai MY, Okushi Y, Jadam S, et al. J Am Coll Cardiol. 2025.

What else moves this marker

They describe those study groups, not an individual, and an association is not a cause.

Genetic predisposition

Each row is one study: what it compared and the change it reported in this marker.
What	Effect on the marker	Comparison · population	Source
↓ CD36 nonsense variant rs3211938:G, homozygotes · LVEF in homozygous carriers without clinical cardiomyopathy, African genetic ancestry	-8 %	Homozygotes vs non-homozygotes, among individuals without clinical cardiomyopathy · Individuals of African genetic ancestry (GWAS of 1,802 DCM cases and 93,804 controls)	gwas · PMID 41174181

Sources

Risk curve: Wang 2003 (PMID 12912813): all-cause HR 1.6 (1.1-2.4) asymptomatic LV systolic dysfunction (visually estimated EF <=50%, no CHF) vs normal systolic function (EF >50%). Scaled to published population values.
Wang et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003;108:977-82.

Map Left Ventricular Ejection Fraction (LVEF) against another biomarker.

Map LVEF against another marker